Reduced Hsp70 and Glutamine in Pediatric Severe Malaria Anemia: Role of Hemozoin in Suppressing Hsp70 and NF-κB Activation

Prakasha Kempaiah,1,2 Karol Dokladny,2 Zachary Karim,1 Evans Raballah,3 John M Ong’echa,1,3 Pope L Moseley,4,5 and Douglas J Perkins1,3

1Center for Global Health; 2Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America; 3University of New Mexico/Kenya Medical Research Institute Laboratories of Parasitic and Viral Diseases, Kisumu, Kenya; 4Departments of Medicine and Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America; and 5Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark

Severe malarial anemia (SMA; hemoglobin (Hb) <5.0 g/dL) is a leading global cause of morbidity and mortality among children residing in Plasmodium falciparum transmission regions. Exploration of molecular pathways through global gene expression profiling revealed that SMA was characterized by decreased HSPA1A, a heat shock protein 70 (Hsp70) coding gene. Hsp70 is a ubiquitous chaperone that regulates nuclear factor-kappa B (NF-κB) signaling and production of proinflammatory cytokines known to be important in malaria pathogenesis (for example, IL-1β, IL-6 and TNF-α). Since the role of host Hsp70 in malaria pathogenesis is unexplored, we investigated Hsp70 and molecular pathways in children with SMA. Validation experiments revealed that leukocytic HSP70 transcripts were reduced in SMA relative to nonsevere malaria, and that intraleukocytic hemozoin (PfHz) was associated with reduced HSP70. HSP70 was correlated with reticulocyte production and Hb. Since glutamine (Gln) upregulates Hsp70, modulates NF-κB activation and attenuates overexpression of proinflammatory cytokines, circulating Gln was measured in children with malaria. Reduced Gln was associated with increased risk of developing SMA. Treatment of cultured peripheral blood mononuclear cells (PBMCs) with PfHz caused a time-dependent decrease in Hsp70 transcripts/protein and NF-κB activation. Gln treatment of PBMCs overcame PfHz-induced suppression of HSP70 transcripts/protein, reduced NF-κB activation and suppressed overexpression of IL-1β, IL-6 and TNF-α. These findings demonstrate that SMA is characterized by reduced intraleukocytic HSP70 and circulating Gln, and that PfHz-induced suppression of HSP70 can be reversed by Gln. Thus, Gln supplementation may offer important immunotherapeutic options for future studies in children with SMA.

Online address: http://www.molmed.org
doi: 10.2119/molmed.2016.00130

INTRODUCTION

Plasmodium falciparum malaria remains one of the most common parasitic diseases around the world and is a leading cause of malaria-related deaths (1). The most common clinical form of falciparum malaria, accounting for the majority of morbidity and mortality, is severe malarial anemia (SMA; hemoglobin [Hb] <5.0 g/dL), which occurs primarily in infants and young children residing in holoendemic P. falciparum transmission areas of sub-Saharan Africa (1–3). Low Hb levels in SMA result from intravascular and extravascular hemolysis and reduced erythropoietic response (4–6). During a malaria infection, the release of cytokines, chemokines and growth factors can cause direct and indirect damage to red blood cells (RBCs) and suppress erythropoiesis by altering the ability of bone-marrow hematopoietic precursor cells to produce new RBCs (2,6–8). However, the underlying molecular pathways that influence the development of SMA remain incompletely characterized. As such, we used clinical and laboratory information collected from our study of 1,643 Kenyan children with malaria
to guide transcriptomic experiments in a subset of individuals with extreme (polarized) clinical phenotypes: mild malaria anemia (non-SMA, nonsevere disease; Hb, 8.0–10.9 g/dL; n = 50, avg. Hb = 10.8 g/dL) and SMA (severe disease; Hb <5.0 g/dL; n = 22, avg. Hb = 4.1 g/dL). These studies identified promising pathways for further studies on susceptibility to SMA, including the 70-kDa heat shock protein (Hsp70) pathway presented here. Considering the key role of Hsp70 as a chaperone, an immunogenic molecule and a protein that delivers and presents antigenic peptides (9), we reasoned that it is critically important for modulating the inflammatory milieu and, consequently, clinical outcomes in children with malaria.

We and others have shown that phagocytosis of *P. falciparum*–derived hemozoin (PfHz) by monocytes, macrophages and neutrophils causes dysregulation in inflammatory mediators that are associated with inefficient erythropoiesis and clinical outcomes in children with malaria, (6,10–13). Additional studies from our group and others have shown that cultured peripheral blood mononuclear cells (PBMCs) treated with physiological concentrations of PfHz have the ability to alter cytokines, chemokines and effector molecules that mimic observations during human falciparum infections (6,14–16). Although the signaling pathways for PfHz require further characterization, nuclear factor–kappa B (NF-κB) appears to be a pivotal transcription factor in a number of inflammatory diseases, since it is a critical upstream regulator of gene expression due to the presence of consensus sequences in the promoter region of inflammatory mediators (16–18). In unstimulated conditions, NF-κB remains bound to its inhibitor, kappa B (IκB), in the cytoplasm as an inactive form (16–18). Following stimulation of cells, IκB is phosphorylated by IκB kinase to rapidly degrade and activate the NF-κB dimer for translocation into the nucleus, where it binds to the enhancer regions on the promoter of target genes (16–18).

Aberrant NF-κB activation has been associated with overabundant inflammatory events in arthritis, asthma, ischemia, septic shock and other autoimmune and inflammatory diseases (19,20). Persistent inhibition of NF-κB activation has been linked to apoptosis, inappropriate immune cell development and delayed cell growth (19). Overexpression of Hsp70 in *in vitro* models inhibits nuclear translocation of NF-κB by preventing degradation of IκB, thereby reducing the elevated production of proinflammatory mediators (20–22). Based on these studies and our transcriptomics experiment, we investigated the role of Hsp70 in modulating NF-κB and Hsp70 in malaria clinical outcomes.

L-glutamine (Gln) is the most abundant amino acid in the human body, stored in circulation and skeletal muscle, and is a modulator of Hsp70 protein through heat-shock factor 1 (HSF1) activation (23–27). *In vitro* and *in vivo* studies demonstrate that Gln upregulates the expression of HSP70 and attenuates over-expression of proinflammatory cytokines (i.e., IL-1β, IL-6 and TNF-α) (25–28). Gln appears to provide protective effects, since it is found to be low in the plasma and skeletal muscle of critically ill patients and is associated with poor clinical outcomes (29). Gln administration is associated with beneficial clinical outcomes in patients with acute illness, chronic inflammation, sepsis or inflammatory injury (28,30,31). In addition, Gln supplementation in mice reduces the severity of septic shock by inhibition of proinflammatory cytokine release through enhanced Hsp70 expression (32).

In studies presented here, we measured HSP70 transcripts, the impact of naturally acquired PfHz on HSP70 expression, and circulating Gln levels in children with varying severity of falciparum malaria. Based on these findings, we then performed experiments in cultured primary human PBMCs to examine the molecular pathways underlying the relationship between PfHz, Hsp70, and NF-κB on its target proinflammatory mediators (IL-1β, IL-6 and TNF-α). Once these relationships were established, we determined the ability of Gln to overcome the PfHz-driven pathophysiological events.

**MATERIALS AND METHODS**

**Study Participants**

Children presenting at Siaya County Referral Hospital in western Kenya, a holoendemic *P. falciparum* transmission area, were recruited at their first hospital visit for the treatment of malaria (3,33). After obtaining written informed consent from the children’s parents or guardians, venipuncture blood samples (<3.0 mL) were collected from enrolled participants before any treatment interventions. Complete blood counts were determined using the Beckman Coulter A'T diff2™ (Beckman-Coultor Corp.). Asexual malaria trophozoites in thick and thin peripheral blood smears and the reticulocyte production index (RPI) were determined according to our previous methods (4). Children were given appropriate treatment and supportive therapy according to the Kenyan Ministry of Health guidelines. Children with *P. falciparum* malaria were classified according to World Health Organization definitions: non-SMA (Hb ≥5.0 g/dL, with any density parasitemia) or SMA (Hb <5.0 g/dL, with any density parasitemia) (34). The current study includes only children with *P. falciparum* parasitemia (n = 144, ages 3–36 months) without any coinfections (i.e., bacteremia or HIV-1).

**Sample Collection and Storage**

From each venous blood sample obtained (<3.0mL), complete hematological measures, sickle-cell trait (HbAS), G6PD deficiency, α-thalassemia, HIV-1 status and bacteremia were determined according to our published methods (3,35). A portion of the blood was also centrifuged to separate the plasma, followed by snap freezing at −80°C until use.

**Inflammatory Mediator and Glutamine Measurements**

Plasma samples were thawed and clarified by centrifugation (13,148×g for 10 min) before assaying. Circulating
inflammatory mediator levels were determined using plasma with the Human Cytokine 25-plex Antibody Bead Kit according to the manufacturer’s instructions. Plates were read on a Luminox® 100™ system and analyzed using the Bio-plex manager software (version IS2.3). The selected analyte detection limits were: 15.0 pg/mL for IL-1β, 5.0 pg/mL for TNF-α and 3.0 pg/mL for IL-6. Gln concentrations were measured by a quantitative colorimetric method using the EnzyChrom™ glutamine assay kit (BioAssay Systems). The lower limit of detection for Gln was 23 μM/L.

Isolation and Culture of Peripheral Blood Mononuclear Cells

PBMCs were isolated and cultured according to our previously described methods (12,36). Briefly, PBMCs (2.5 × 10⁶ cells/mL) were cultured in 6-well plates under both physiological (37°C) and heat shock treatment (42°C) for 2 h prior to stimulation with lipopolysaccharide (LPS) (Escherichia coli LPS 0127B8, 200 ng/mL) (Alexis Corp.) for 1 h, followed by presence or absence of PHz (10 μg/mL) and Gln (0.5, 2.0, and 4.0 mM) pretreatment for 30 min prior to adding PHz.

Hemozoin Preparation

Crude PHz was isolated from mycoplasma-negative in vitro cultures of P. falciparum infected red blood cells as described previously (37). Briefly, P. falciparum (Pfd6 strain) infected RBCs were collected when parasitemia was >5% with late-stage trophozoites and early schizonts as the predominant forms. Cultures were centrifuged at 1,308 g for 10 min and the pellet was resuspended in 40 mL of 0.01 M phosphate-buffered saline (PBS; pH 7.2) containing 1% saponin (Sigma) and incubated for 10 min. Culture lysate was examined microscopically (in a hemocytometer) to ensure that the RBCs were completely lysed. Lysates were centrifuged at 13,148 g for 15 min. The pellet was resuspended and washed 7 × with PBS until the supernatant was clear, and then sonicated 2 × to remove the lipids. The final pellet was dried at 40°C overnight, weighed and resuspended in filter-sterilized endotoxin-free H₂O at 1.0 mg/mL. Endotoxin level in the PHz preparation was <0.1 EU/mL as determined by the Limulus amebocyte lysate test (Thermo Fisher). Since 5.0 EU/mL is equal to 1 ng/mL of endotoxin, there was less than 0.02 ng/mL of endotoxin in the preparation.

PCN and PCM Quantification

Venous blood (≤3.0 mL) was collected from the study participants as stated earlier. Both thin and thick blood smears were prepared to determine the presence of parasites by counting the number of asexual stage parasites per 300 white blood cells. Measurements of pigment-containing monocytes (PCMs) and pigment-containing neutrophils (PCNs) were determined on Geimsa-stained slides per previous methods (4). Enumeration of PCMs and PCNs was determined and expressed as the number of pigment-containing cells per microliter of blood.

Transcriptome Analysis

For global gene expression analyses, 72 samples were selected to represent “polarized extremes” of clinical phenotypes from a group of 1,643 children: mild malaria anemia (non-SMA, nonsevere disease; Hb, 8.0–10.9 g/dL; n = 50, avg. Hb = 10.8 g/dL) and SMA (severe disease; Hb <5.0 g/dL; n = 22, avg. Hb = 4.1 g/dL). Children with coinfections (i.e., HIV-1 or bacteriaemia) were excluded from analysis since we have shown that these pathogens influence clinical disease outcomes (6,7,35). Total RNA was isolated from WBC pellets collected on presentation at the hospital (d 0) prior to any treatment interventions using the GITC method (36,38). Following quality check and quantification, global gene expression profiling was performed using the Illumina® HumanHT-12 v4 beadchip covering >47,000 transcripts on the Illumina GenomeStudio® iScanSQ platform. The Illumina GenomeStudio® was used to subtract the background signal from the transcript signal, which generated a list of 19,185 transcripts. Gene expression data underwent further selection with stepwise procedures using GeneSpring GX software (Agilent Technologies) to remove transcripts identified as having an “absent” expression for quality control.

In Vitro Gene Expression Assays

RNA was isolated from circulating white blood cells obtained from children with malaria using the GITC method (36,38) and in vitro PBMC cultures using the RNEasy® mini kit (Qiagen) according to the manufacturer’s instructions. From 1.0 μg of total RNA, complementary DNA (cDNA) was prepared with the transcriptor first strand cDNA synthesis kit (Roche). For measurement of HSPA1A, HSPA1B, IL-1β, IL-6 and TNF-α gene expression levels, 0.5 μg of resulting cDNA was used for gene-specific TaqMan® qPCR assays. The constitutively expressed housekeeping gene β-actin was used as an endogenous control to normalize the target gene expression data in a quantitative gene expression assay on the StepOnePlus™ Real-Time PCR System (ABI).

Immunoblot Assays

Both floating and adherent cells from PBMC cultures were harvested and washed twice with cold PBS by centrifugation. For preparation of total crude lysates, cells (4 × 10⁶) were lysed in 250 μL of buffer containing of 125 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 50 mM sodium phosphate, 1 mM PMSF and protease inhibitor cocktail (Sigma). Resulting lysates were kept on ice for 10 min and centrifuged for 15 min at 10,000 × g at 4°C, and recovered supernatants were stored at −80°C until use. To quantify Hsp70 protein, samples were prepared by boiling supernatants in 4 × Laemmli sample buffer (Bio-Rad Laboratories) for 5 min and loaded (50 μg of proteins) onto SDS-PAGE (4–20% polyacrylamide gradient) gels. Following electrophoresis, proteins were electrotransferred to nitrocellulose membranes (Bio-Rad Laboratories), and subsequently blocked with 5% blotting...
grade nonfat dry milk (Bio-Rad Laboratories) in TBS/0.1% Tween-20 at RT for 1 h. Membranes were then probed with anti-Hsp70 antibody (Assay Designs) dissolved in fresh blocking buffer. Separate immunoblots were also generated by stripping the membranes to verify equal loading of lysate proteins using anti-β-actin antibody (for total protein) (Sigma). Immunoreactive proteins were identified using HRP-conjugated secondary antibodies (Cell Signaling) and a chemiluminescent reagent system.

To facilitate quantification of NF-κB translocation into the nucleus, cytosolic and nuclear fractions were prepared from the freshly harvested cells using the nuclear extract kit (Active Motif) according the manufacturer’s instructions. Equal amounts of protein were loaded on to 4-20% SDS-PAGE and probed with NF-κB (p65, C-term) antibody (GeneTex) dissolved in fresh blocking buffer. Separate immunoblots were generated by stripping the membranes to verify equal loading of lysate proteins using either anti-β-actin antibody (for total protein), or the integrity of the nuclear fraction was verified with anti-histone-H1 antibody (GeneTex). Immunoreactive proteins were identified using HRP-conjugated secondary antibodies and a chemiluminescent reagent system.

Data Analysis

Differences in circulating inflammatory mediators, Gln and laboratory variables were determined using nonparametric Mann-Whitney U test for group comparisons, and Chi-square tests for differences in proportions between non-SMA and SMA groups (SPSS version 19.0 for Windows, SPSS Inc.). Logistic regression, controlling for age, gender and parasitemia, was used to examine association between Gln levels and SMA (SPSS version 19.0). Global gene expression data was analyzed using the GeneSpring GX software (Agilent Technologies) and correlation tests were performed using the GraphPad Prism 5° (GraphPad Software Inc.) software. Analysis of variance (ANOVA) tests were used to compare gene expression levels across the groups. Bivariate analysis of normalized HSP70 (1A + 1B) gene expression between the two groups was performed using unpaired two-tailed t test and presented as mean (SEM). The nonparametric Spearman’s rank correlation co-efficient (r) test was used to determine the association between circulating mediators and factors influencing SMA (i.e., Hb and reticulocyte production index). Densitometry quantification of immunoblots was performed using ImageJ software (Windows version of National Institutes of Health’s Image, http://rsweb.nih.gov/ij/download.html). The intensities are reported in arbitrary units (A.U.), obtained by subtracting the background value from the corresponding band’s mean values determined after normalizing with housekeeping proteins (i.e., β-actin and histone-H1, respectively). Statistical significance for all analyses was set at P ≤ 0.050.

All supplementary materials are available online at www.molmed.org.

RESULTS

Clinical and Laboratory Characteristics of the Study Participants

Parasitemic children (n = 144) were stratified, based on Hb concentration, into two clinical categories: non-SMA (Hb ≥5.0 g/dL) and SMA (Hb <5.0 g/dL) (34). Data are presented in Table 1. Children with SMA were significantly younger than those with non-SMA (P = 0.007).

A number of hematological indices also differed between the two groups, with SMA characterized by elevated WBCs (P = 0.005) and monocytes (P = 0.037), and reduced granulocytes (P = 0.051) and platelets (P = 0.042). As expected based on the a priori grouping according to Hb levels, children with SMA had

<p>| Table 1. Clinical and laboratory characteristics of the study participants. |
|-----------------------------|-----------------------------|-----------------------------|</p>
<table>
<thead>
<tr>
<th><strong>Characteristic</strong></th>
<th>Non-SMA (Hb ≥ 5.0 g/dL)</th>
<th>SMA (Hb &lt; 5.0 g/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>93</td>
<td>51</td>
</tr>
<tr>
<td>Age, months</td>
<td>12.03 (10.00)</td>
<td>7.38 (5.77)</td>
</tr>
<tr>
<td>Gender: male/female **</td>
<td>52/41</td>
<td>22/28</td>
</tr>
<tr>
<td>Glucose (mMol/L)</td>
<td>4.90 (1.00)</td>
<td>5.10 (1.00)</td>
</tr>
<tr>
<td>Temperature (°C)</td>
<td>37.40 (2.0)</td>
<td>37.30 (1.0)</td>
</tr>
<tr>
<td>White blood cells (x10^9/μL)</td>
<td>11.60 (5.70)</td>
<td>14.95 (8.55)</td>
</tr>
<tr>
<td>Lymphocytes (x10^3/μL)</td>
<td>49.00 (23.05)</td>
<td>51.05 (12.55)</td>
</tr>
<tr>
<td>Monocytes (x10^3/μL)</td>
<td>8.40 (4.90)</td>
<td>10.15 (7.95)</td>
</tr>
<tr>
<td>Granulocytes (x10^3/μL)</td>
<td>42.10 (26.00)</td>
<td>37.90 (16.80)</td>
</tr>
<tr>
<td>Hemoglobin (Hb, g/dL)</td>
<td>7.90 (5.05)</td>
<td>4.20 (1.10)</td>
</tr>
<tr>
<td>Hematocrit (Hct, %)</td>
<td>23.70 (14.20)</td>
<td>13.05 (3.40)</td>
</tr>
<tr>
<td>Red blood cells (x10^9/μL)</td>
<td>3.58 (1.57)</td>
<td>1.85 (0.85)</td>
</tr>
<tr>
<td>Platelets (x10^3/μL)</td>
<td>171 (134)</td>
<td>141 (85)</td>
</tr>
<tr>
<td>Parasite density (μL)</td>
<td>24,991 (54,895)</td>
<td>23,661 (62,758)</td>
</tr>
<tr>
<td>Pigment-containing monocytes (PCM), n (%)</td>
<td>45 (48.39)</td>
<td>39 (76.47)</td>
</tr>
<tr>
<td>Pigment-containing neutrophils (PCN), n (%)</td>
<td>6 (6.0)</td>
<td>11 (21.57)</td>
</tr>
<tr>
<td>Pigment-containing monocytes (PCM), n (%)</td>
<td>10.52 (1.95)</td>
<td>41.25 (7.10)</td>
</tr>
<tr>
<td>Pigment-containing neutrophils (PCN), n (%)</td>
<td>0.34 (0.14)</td>
<td>5.31 (1.88)</td>
</tr>
<tr>
<td>Reticulocyte production index</td>
<td>58 (62.37)</td>
<td>47 (92.16)</td>
</tr>
</tbody>
</table>

Parasitemic children (n = 144) were stratified into non-SMA (i.e., Hb ≥5.0 g/dL) and SMA (i.e., Hb <5.0 g/dL) (34). Data presented are medians (interquartile range, IQR), unless otherwise stated. **Statistical significance determined by Mann-Whitney U test. *Statistical significance determined by Chi-square analysis. Statistical significance determined by independent samples t test.
lower Hb concentrations \((P < 0.0001)\), hematocrit \((P < 0.0001)\) and RBC counts \((P < 0.0001)\). Of note, peripheral malaria parasite density did not differ between the two groups \((P = 0.928)\). Examination of circulating \(PfHz\)-containing leukocytes revealed that children with SMA had a higher percentage of PCM \((P = 0.001)\) and PCN \((P = 0.007)\), as well as elevated levels of PCM/\(\mu\)L \((P < 0.0001)\) and PCN/\(\mu\)L \((P < 0.0001)\). Children with SMA also had a higher percentage of inefficient erythropoiesis, characterized by RPI <2.0 \((P < 0.0001)\). Taken together, these results illustrate that children with SMA have distinct hematological profiles in the context of comparable peripheral parasite burden and enhanced phagocytosis of \(PfHz\) by circulating neutrophils and monocytes, as we have previously shown (4,6,39).

**Ex Vivo HSP70 Gene Expression in Children with Malaria**

To identify promising gene pathways that could potentially mediate the clinical outcomes in children with severe malaria, global gene expression was performed with the Illumina® HumanHT-12 v4 beadchip array. As mentioned above, the transcriptomics experiments utilized a subset of malaria-infected individuals with polarized clinical phenotypes to enhance discovery of potentially important signals by comparing extreme groups and removing ambiguous signals that may overlap in children with non-SMA versus SMA. Among a number of important signals that emerged from the transcriptomics experiments, children with SMA had significantly lower \(HSPA1A\) transcripts than children with mild malaria (non-SMA, \(P = 0.034\), Figure 1A). Based on these results and the importance of Hsp70 in innate immunity (9,21,22,40–42), we validated gene expression profiles for \(HSPA1A\) and also measured \(HSPA1B\) (which was not present in the transcriptomics array). This approach allowed us to account for total HSP70 expression (\(HSPA1A\) and \(HSPA1B\)) in the non-SMA and SMA groups. Gene expression levels for \(HSPA1A\) and \(HSPA1B\) were significantly lower in the SMA group \((P < 0.001\) and \(P = 0.050\), respectively), as were the combined \(HSPA1A/1B\) data representing total HSP70 transcript levels \((P < 0.001\), Figure 1B).

Since we have shown that levels of intraleukocytic \(PfHz\) are strongly associated with circulating inflammatory mediator production and suppression of intracellular proteins that regulate immune responses in children with falciparum malaria (36,39,43), we reasoned that phagocytosis of malarial pigment may also be an important mechanism through which Hsp70 is downregulated. As such, \(HSP70\) gene expression was stratified according to absence/presence of \(PfHz\) in circulating monocytes (PCMs) and neutrophils (PCNs), respectively. Presence of naturally acquired intracellular \(PfHz\) in both monocytes and neutrophils was associated with significantly lower \(HSP70\) transcript levels \((P = 0.010\) and \(P = 0.019\),

---

**Figure 1.** \(HSP70\) gene expression in children with malaria. (A) Parasitemic children \((n = 72)\) were categorized according to “polarized” phenotypic clinical categories of non-SMA (Hb 8.0–10.9 g/dL, \(n = 50\)) and SMA (Hb <5.0 g/dL, \(n = 22\)). Global gene expression profiling was performed on total RNA isolated from WBCs using the Illumina® HumanHT-12 v4 beadchip array covering >47,000 transcripts. Panel A shows \(HSPA1A\) gene expression analysis. aBivariate analysis of \(HSPA1A\) gene expression between two groups was performed using unpaired \(t\) test and presented as mean (SEM). (B) \(HSPA1A/1B\) and \(HSP70\) gene expression analysis using qRT-PCR on WBCs collected from parasitemic children \((n = 73)\) stratified into non-SMA (Hb ≥5.0 g/dL, \(n = 52\)) and SMA (Hb <5.0 g/dL, \(n = 21\)). The cyclophilin-A gene was used as an endogenous control to normalize expression. Bivariate analysis of normalized \(HSPA1A/1B\) gene expression (arbitrary units, AU) between two groups was performed using unpaired non-tailed \(t\) test and presented as mean (SEM). (C) \(HSP70\) gene expression in \(PfHz\)-containing monocytes and neutrophils. Bivariate analysis of normalized \(HSP70\) (\(1A + 1B\)) gene expression between \(PfHz\)-containing monocytes and neutrophils. \(PfHz\) (-) monocytes \((n = 22)\), \(PfHz\) (+) monocytes \((n = 51)\); \(PfHz\) (-) neutrophils \((n = 65)\), and \(PfHz\) (+) neutrophils \((n = 8)\). Bivariate analysis of normalized \(HSPA1A/1B\) gene expression (arbitrary units, AU) between two groups was performed using unpaired non-tailed \(t\) test and presented as mean (SEM).
with malarial anemia, we examined the time-dependent (i.e., 2, 8, 24 and 48 h) effect of physiological concentrations of PfHz (10 μg/mL) (37) on Hsp70 transcripts and protein in cultured PBMCs. In addition, since heat-shock treatment (42°C) induces overexpression of Hsp70 (45), the time-dependent effects of PfHz on Hsp70 were examined under both physiological (37°C) and heat-shock conditions (2 h pretreatment exposure). Because it is a challenge to determine decreased gene expression in response to PfHz without first inducing expression of the gene(s) of interest that are often expressed at low levels in PBMCs from noninfected individuals, cells were pretreated with LPS for 1 h. Based on the lack of in vivo priming in healthy individuals, LPS can be used to generate higher basal levels of genes, particularly those that are downregulated by pathogen products, so that in vitro investigations can be performed from blood isolated from healthy donors (22,36,46,47). Addition of PfHz reduced LPS-induced expression of HSP70 transcripts in a time-dependent manner under both physiological and heat-shock conditions (Figure 3A). To confirm that changes in HSP70 transcripts corresponded with functional changes in Hsp70 protein, relationship between HSP70 transcripts, RPI and Hb concentrations were examined. Our previous studies have shown that ineffective erythropoiesis, represented by determining RPI, is an important mechanism for promotion of anemia in children with malaria (4). As shown in Figure 2, there was a positive correlation between HSP70 transcripts and both RPI (ρ = 0.208, P = 0.002, Figure 2A) and Hb concentrations (ρ = 0.182, P = 0.006, Figure 2B). These results suggest that reduced HSP70 expression in children with malaria may play an important role in promoting inefficient erythropoiesis that culminates in enhanced anemia.

**Effect of Hemozoin on Hsp70**

Results obtained in children with malaria demonstrated that SMA is characterized by reduced HSP70 transcripts in peripheral blood, and that phagocytosis of PfHz by circulating leukocytes may be an important event in causing suppression of Hsp70. Although previous studies showed that malarial pigment increases expression of Hsp27, a chemokine-related heat-shock protein with antiapoptotic properties (14), the effect of PfHz on Hsp70 has not been reported. Based on this previous finding and results presented here in children with malarial anemia, we examined the time-dependent (i.e., 2, 8, 24 and 48 h) effect of physiological concentrations of PfHz (10μg/mL) (37) on Hsp70 transcripts and protein in cultured PBMCs. In addition, since heat-shock treatment (42°C) induces overexpression of Hsp70 (45), the time-dependent effects of PfHz on Hsp70 were examined under both physiological (37°C) and heat-shock conditions (2 h pretreatment exposure). Because it is a challenge to determine decreased gene expression in response to PfHz without first inducing expression of the gene(s) of interest that are often expressed at low levels in PBMCs from noninfected individuals, cells were pretreated with LPS for 1 h. Based on the lack of in vivo priming in healthy individuals, LPS can be used to generate higher basal levels of genes, particularly those that are downregulated by pathogen products, so that in vitro investigations can be performed from blood isolated from healthy donors (22,36,46,47). Addition of PfHz reduced LPS-induced expression of HSP70 transcripts in a time-dependent manner under both physiological and heat-shock conditions (Figure 3A). To confirm that changes in HSP70 transcripts corresponded with functional changes in Hsp70 protein,
the time-dependent effect of PfHz on protein levels was determined. Consistent with the gene expression profiling, PfHz decreased LPS-induced Hsp70 protein in a time-dependent fashion under physiological and heat-shock conditions (Figures 3B and C). These results provide support for the ex vivo measurements of Hsp70 transcripts in children with malaria, showing that the presence of intraleukocytic PfHz is associated with significantly reduced HSP70 (Figure 1C). In addition, as shown in Supplementary Figure 2, PfHz alone induced a slight downregulation of HSP70 gene expression, which was less pronounced than that observed in LPS-treated cells that were primed for 1 h prior to addition of PfHz (P = 0.301), suggesting that the effect of PfHz on HSP70 is not unique to LPS.

**Effect of Hemozoin on NF-κB Activation**

Previous in vitro studies showed that hemozoin causes increased translocation of NF-κB into the nucleus and enhanced expression of proinflammatory cytokines (14,37,48,49). Conversely, overproduction of Hsp70 leads to reduced NF-κB signaling and decreased proinflammatory cytokine production (50,51). The link between PfHz, Hsp70 and NF-κB translocation into the nucleus, however, has not been established. As such, cultured PBMCs were stimulated with PfHz under identical conditions as outlined above for the Hsp70 experiments, and the time-dependent translocation of NF-κB into the nucleus was examined. As shown in Figures 4A and B, LPS induced translocation of NF-κB protein into the nucleus as early as 2 h and increased thereafter at both 37°C and 42°C. Importantly, the addition of PfHz caused further enhancement of NF-κB translocation into the nucleus, with peak expression at 8 h under physiological (37°C) and heat-shock conditions (42°C, Figures 4A and B). Consistent with the fact that heat-shock treatment increases Hsp70 and thereby reduces NF-κB translocation into the nucleus (20–22), the effect of PfHz on NF-κB at 42°C was not as pronounced as that observed at 37°C (Figures 4A and B).

**Circulating Glutamine Levels in Children with Malaria**

Low plasma Gln levels are associated with poor clinical outcomes, shock and increased risk of mortality in hospitalized patients (30,31). In addition, low plasma Gln concentrations (<420 μmol/L) are an independent risk factor for mortality and multiple organ failure in critically ill adults and children, respectively (30,52). As such, we measured circulating Gln levels in children with non-SMA (n = 37) and SMA (n = 31). Gln levels were significantly reduced in children with SMA (484 (142–920)) compared with those with non-SMA (1361 (182–1816), P < 0.0001; Figure 5A). To further explore the relationship between plasma Gln levels and SMA, children were stratified into two groups based on low plasma Gln concentrations: <420 μmol/L (n = 20) and >420 μmol/L (n = 48). Logistic regression analysis, controlling for age, gender and parasitemia, revealed that plasma Gln levels <420 μmol/L were associated with a seven-fold higher risk of developing SMA (OR 7.31; 95% CI 1.82–29.41;...
stratified plasma Gln concentrations as two standard deviations (SDs) below the mean (2 SDs from mean = 598). Logistic pediatric cohort (53), we took an unbiased approach to represent the distribution within the population and

\[ P < 0.01; \text{Figure 5B} \]. Although the commonly used adult cutoff value of 420 μmol/L has been validated in one pediatric cohort (53), we took an unbiased approach to represent the distribution within the population and stratified plasma Gln concentrations as two standard deviations (SDs) below the mean (2 SDs from mean = 598). Logistic
regression analyses controlling for identical covariates demonstrated that children with plasma Gln concentrations <598 μmol/L (n = 29) had a 24-fold higher risk of developing SMA (OR 24.65; 95% CI 5.47-111.15; P < 0.0001; Figure 5B). Thus, low plasma Gln levels in children with malaria are associated with a highly significant risk for developing SMA.

Since Gln is known to increase HSP70 gene expression (23,25–28), the relationship between circulating Gln and HSP70 transcripts was determined in children with malaria. As shown in Figure 5C, transcripts was determined in children ship between circulating Gln and HSP70 gene expression (23,25–28), the relation-

### Effect of Glutamine on Hemozoin-Induced Suppression of Hsp70

Since circulating levels of Gln were significantly reduced in children with SMA (see Figure 5A), and Gln improves clinical outcomes in acute illness and injury through increasing Hsp70 expression, an event that attenuates NF-κB translocation to nucleus (28,41,54), we determined whether the addition of Gln could overcome PfHz-induced suppression of Hsp70 and activation of NF-κB. As shown in Figure 6A, treatment of cells with Gln dose-dependently (0.5, 2.0 and 4.0 mM) enhanced HSP70 transcripts in the presence of PfHz throughout the time-course experiment (P < 0.05 for Gln treatments at all time points versus LPS and PfHz). To confirm that the transcriptional changes induced by Gln were also present at the protein level, Hsp70 protein expression was determined at 24 h. Consistent with the mRNA experiments, phagocytosis of PfHz reduced Hsp70 production and treatment with Gln dose-dependently rescued the inhibitory effect of PfHz on Hsp70 (Figures 6B and C). Thus, treatment with Gln can overcome PfHz-induced suppression of Hsp70. To confirm that the observed effects were not unique to LPS-treated conditions, additional experiments were performed using Gln and PfHz alone and in combination, without LPS stimulation. The results show that PfHz alone had an inhibitory effect on Hsp70 protein relative to control (P = 0.032). These investigations demonstrated identical, albeit less pronounced, results in the absence of LPS priming (Supplementary Figure S3).

### Effect of Glutamine on NF-κB Activation

Next, we performed time-series (1, 2, 4, 8, 24 and 48 h) experiments to determine whether dose-dependent stimulation with Gln (0.5, 2.0 and 4.0 mM) attenuates NF-κB translocation into the nucleus. In nonstimulated conditions, Gln had no effect on activation of NF-κB (Figures 7A and B). However, treatment of cells with Gln was able to reverse the induction of NF-κB promoted by PfHz and cause a dose- and time-dependent decrease in NF-κB translocation into the nucleus (Figures 7A and B). Demonstrating that Gln treatment can prevent the activation of NF-κB induced by phagocytosis of hemozoin.

### Effect of Glutamine on Proinflammatory Mediators Modulated by HSP70 and NF-κB

Previous studies demonstrated that Gln increases Hsp70 protein production, resulting in attenuation of NF-κB translocation into the nucleus and, consequently, reduced proinflammatory cytokine (IL-1β), IL-6 and TNF-α production (14,42,48). We and others have shown that dysregulation of these same

---

**Figure 6.** Effect of glutamine treatment on PfHz-mediated inhibition of HSP70. (A) Peripheral blood mononuclear cells (2.5 × 10⁶) were incubated with LPS for 1 h prior to addition of Gln (0.5, 2.0 and 4.0 mM, pretreated 30 min prior to adding PfHz) for different time points. Total RNA was isolated and gene expression analysis by qRT-PCR was performed to quantify the HSP70 (1A + 1B) transcripts, using TaqMan® gene expression assays. β-actin was used as an endogenous control to normalize the data by the ΔΔCT method. Data represent average of individuals (n = 3) with each condition performed in triplicate (error bars represent SEM). * indicates P < 0.05 (one-way ANOVA) relative to LPS + PfHz treated cells. (B) Experiments performed as outlined in A showing the effect of Gln (0.5, 2.0 and 4.0 mM) on PfHz-mediated inhibition of Hsp70 assessed using immunoblotting at 24 h. (C) Densitometry analysis was performed to quantify intensity of expression. Data shown after normalizing Hsp70 relative to β-actin (n = 3); error bars represent SEM.
proinflammatory mediators are also associated with clinical outcomes in children with malaria (6,7,44,55). Since we found that Gln can overcome PfHz-induced suppression of Hsp70 and decrease NF-kB translocation into the nucleus, we determined whether Gln treatment could also prevent overexpression of IL-1β, IL-6 and TNF-α. As shown in Figures 8A–C, stimulation of cells with LPS and PfHz caused a time-dependent increase in IL-1β, IL-6 and TNF-α transcript levels. Addition of Gln (0.5, 2.0 and 4.0 mM) dose-dependently reduced transcriptional expression of all three inflammatory mediators \( (P < 0.05 \) for Gln treatments at all time points versus LPS + PfHz; Figures 8A–C). Collectively, these in vitro results demonstrate that Gln treatment rescues the inhibitory effect of PfHz-induced suppression of Hsp70 and overexpression of NF-kB–modulated proinflammatory cytokines that promote SMA (reviewed in (6)). Consistent with our previous approach, additional investigations were performed using Gln and PfHz alone and in combination, without LPS stimulation. These experiments confirmed that the effect of Gln on cytokine responses in PfHz-treated cells was independent of the priming (IL-1β \( [P = 0.022], \) TNF-α \( [P = 0.002] \) and IL-6 \( [P = 0.007] \)), and more robust responses generated by pretreatment with LPS (Supplementary Figures 4 and 5).

**DISCUSSION**

For more than a decade, we have been investigating the impact of altered immunity on the development of SMA. In particular, we have primarily focused on the innate immune response, because the infants and young children who develop SMA have not acquired robust antibody-mediated immunity, an important hallmark for protection against severe disease. Since our studies are conducted in a holoendemic *P. falciparum* transmission region of western Kenya, nearly all the children get repeated episodes of malaria prior to developing naturally acquired immunity. Given that malaria pathogenesis is complex and, arguably, poorly understood, we sought to take an unbiased discovery approach. As such, we utilized the Illumina® HumanHT-12 v4 bead-chip, which covers >47,000 transcripts, to catalogue global gene expression in children with malaria. To maximize the probability of finding important signals, we used the larger cohort of children to guide selection of malaria-infected individuals who were stratified into extreme phenotypes and compared the “sickest” individuals with the lowest Hb levels against the “healthiest” children with the highest Hb levels present during a malaria infection.
Figure 8. Effect of glutamine treatment on PfHz-mediated inhibition of proinflammatory mediators (IL-1β, TNF-α, and IL-6). Peripheral blood mononuclear cells (2.5 × 10⁶) were incubated with LPS for 1 h prior to Gln treatment (0.5, 2.0 and 4.0mM, pretreated 30 min prior to adding PfHz) for different time points. Total RNA was isolated and gene expression analysis by qRT-PCR was performed to quantify the cytokine transcripts using TaqMan® gene expression assays. β-actin was used as an endogenous control to normalize the data by the ΔΔCT method. Data represent average of individuals (n = 3) with each condition performed in triplicate (error bars represent SEM). * indicates P < 0.05 (one-way ANOVA) for Gln treatment relative to LPS + PfHz. (A) IL-1β mRNA fold change. (B) TNF-α mRNA fold change. (C) IL-6 mRNA fold change.

One of the genes that emerged as significantly different between the two groups in the transcriptomics experiments was HSPA1A. This finding warranted high priority for further exploration, since the heat-shock response via Hsp70 expression is an integral part of innate immunity that protects against inflammatory insults in response to cellular stress and infections (9,40,56–61). As such, the ability to induce functional HSP70 gene products represents an early cellular event that can dramatically impact subsequent immunological responses. Since the heat-shock response and, in particular, dysregulation in Hsp70 has not been reported as part of the host immune response to human malaria, we first sought to validate the global gene expression results by measuring HSPA1A and HSPA1B (cumulatively representing Hsp70) in additional malaria-infected individuals stratified into non-SMA and SMA. These experiments confirmed that HSP70 transcripts were significantly lower in children with severe disease, suggesting that dysregulation of Hsp70 may be associated with the pathogenesis of malaria, just as it is in other multifactorial diseases, including infectious diseases (e.g., severe sepsis, tuberculosis and leprosy), stress, and autoimmune and inflammatory diseases (40,56,58,59,61–64).

To gain insight into the mechanism(s) by which HSP70 transcripts are suppressed in malaria, we stratified children with malaria into those with and without naturally acquired hemozoin in their circulating monocytes and neutrophils. The rationale for investigating hemozoin in circulating leukocytes as a source of lower HSP70 in children with severe disease was driven by experiments in our laboratory over the past decade. These investigations demonstrated that phagocytosis of PfHz is an important driver of dysregulation in cytokines, chemokines and effector molecule genes in children with SMA (reviewed in (6)). The ability of hemozoin to alter the innate immune response to malaria, and thereby enhance the anemia of inflammation, is supported by our findings showing that elevated levels of PfHz in circulating leukocytes are a significant predictor of SMA (11,37,65). Stratification of children with malaria based on the presence and absence of PfHz in monocytes and neutrophils revealed significantly lower HSP70 transcripts in the presence of naturally acquired hemozoin, suggesting that phagocytosis of PfHz may be a potential source of altered HSP70 gene expression. It is unclear whether the effect is due to phagocytosis of PfHz or through molecules that are both conjugated with and produced by PfHz. For example, PfHz carries and induces the cellular production of 15(S)-hydroxyeicosatetraenoic acid (15-HETE) and 4-hydroxynonenal (4-HNE), both of which could act on blood cells in vivo and in vitro upon exposure to hemozoin (66,67). Thus, it remains to be determined if the effects of PfHz on immune activation and the promotion of anemia are acting through hemozoin-promoted lipoperoxidation (68).

Prior to proceeding with additional investigations, we sought to determine whether the levels of HSP70 expression were associated with the primary clinical manifestations of SMA we established in holoendemic P. falciparum transmission regions: inefficient erythropoiesis leading to reduced Hb concentration (4,7,39,69). There was a significant positive correlation between HSP70 transcripts and the reticulocyte production index and Hb levels, thus indicating that induction of a robust Hsp70 response is correlated with more efficient erythropoiesis and lower levels of anemia. This clinical finding in children with anemia is consistent with previous studies showing that Hsp70 is an important positive regulator of erythropoiesis (70,71). After establishing that reduced HSP70 transcripts were associated with
enhanced disease severity in children with malaria, and that naturally acquired phagocytosis of hemozoin may be a driving factor in lower Hsp70, we performed a series of in vitro experiments to definitively establish this potential molecular mechanism. Incubation of cultured PBMCs with physiologically relevant concentrations of PfHz (37) caused a time-dependent decrease in the major HSP70 coding transcripts (HSPA1A and HSPA1B) and Hsp70 protein, demonstrating that the transcriptional changes induced by PfHz affect functional Hsp70 protein levels. Previous studies from our group have shown increased Hsp70 in the context of elevated temperature in both animal models and cultured cells (45). As such, cultured PBMCs were exposed to PfHz at 42°C. There was a 5.88-fold increase in the expression of HSP70 transcripts due to heat-shock treatment by 24 h that was significantly reduced by the presence of PfHz. Immunoblot experiments revealed that maximal PfHz-induced suppression of Hsp70 under heat-shock conditions was present by 48 h, just as it was at 37°C. This series of in vitro experiments demonstrate that phagocytosis of hemozoin can suppress Hsp70 transcripts and protein.

Accumulating evidence suggests that the protective (antiinflammatory) role of Hsp70 is mediated through downregulation of NF-κB, since NF-κB activation and translocation into the nucleus promotes elevated proinflammatory mediators (14,16–21,41,50,72,73). Consistent with this notion, we and others have demonstrated that overexpression of Hsp70 protein blocks nuclear translocation of NF-κB and thereby reduces proinflammatory mediator production (19–21,50). Although the role of Hsp70 in modulating the inflammatory response through interference with NF-κB activation has been shown in several diseases (9,74–76), the link between Hsp70, NF-κB activation and cytokine production has not been established in human malaria. However, a number of previous in vitro studies have shown that hemozoin and other parasitic products induce the production of inflammatory mediators through NF-κB activation (16). Results presented here show that PfHz induces rapid translocation of NF-κB into the nucleus with peak levels by 8 h. In addition, after induction of Hsp70 with elevated temperature (42°C), PfHz remained capable of causing NF-κB activation, although to a lesser extent due to enhanced Hsp70 expression.

Reduced Gln levels have been associated with numerous adverse clinical outcomes, such as increased coinfections; sepsis; inflammatory, epithelial, hemopoietic and exercise-induced permeability, organ injury, etc. (23,28,30,31,77,78). Although low circulating Gln concentrations (<420 μmol/L) are associated with increased mortality in critically ill adults (30,52), there is little information available about the relationship between plasma Gln and morbidity and mortality in severely ill children. Several studies suggest that similar characteristics for Gln metabolism may exist between adult and pediatric populations. For example, severely ill neonates have low plasma Gln concentrations (79,80). It was also recently shown that low plasma Gln levels in critically ill children are associated with a higher incidence of multiple organ failure and longer duration of stay in the pediatric intensive care unit (53). Results presented here extend these previous investigations by demonstrating that children with SMA have significantly lower plasma Gln levels, and that low circulating Gln concentrations are associated with a highly significant increase in the risk of developing severe malaria. Lower levels of circulating Gln have also been reported in Ghanaian children with acute falciparum malaria compared with control cases (81). However, our finding that low levels of Gln in children with malaria are associated with enhanced disease severity appears to differ from a previous finding in Gabonese children with malaria, in which plasma Gln concentrations were higher in children with severe versus moderate disease, and highest in those who died compared with those who survived (82). Although we did not directly compare the Gln levels in children who died of severe malaria, since there were only two deaths in this study population, potential differences across the studies may be due to the case definition of severe malaria. For example, the Gabonese study included a definition of severe disease defined by one or more of the following: Blantyre coma score ≤2, repeated witnessed convulsions (≥3), lactate ≥5 mmol/L, glucose ≤2.2 mmol/L and severe anemia (Hb <5.0 g/dL or hematocrit <15%), whereas the definition of severe disease in our study included only children with SMA (Hb <5.0 g/dL in the presence of any density parasitemia). The definition of severe disease used in the current study was based on the fact that cerebral malaria is exceedingly rare in the region (83). This distinction may be important in the context of recent findings in murine experimental cerebral malaria, in which administration late in the infection of a glutamine analog, 6-diazo-5-oxo-L-norleucine, which broadly inhibits Gln metabolism, rescues mice from the manifestations of severe disease, including blood-brain barrier dysfunction, brain swelling and hemorrhaging, and accumulation of parasite-specific CD8⁺ effector T cells and infected red blood cells in the brain (84). It remains to be determined if Gln supplementation as an adjunctive treatment in the context of antimalarial chemotherapy provides differing clinical outcomes in children with cerebral malaria versus those with SMA. In any event, data presented in the current cohort of children clearly show that low circulating Gln levels are associated with more severe disease. Although the physiological actions of Gln are diverse, numerous studies show that therapeutic supplementation with Gln has beneficial effects through the promotion of enhanced HSP expression (25–28). Moreover, Gln-mediated induction of the heat-shock response is an important part of the innate immune response, since Gln is critical for protection and recovery from tissue injury and stress-related inflammation (23,28,76,85).
Additional studies have shown that macrophages require high levels of Gln to successfully produce inflammatory mediators as part of the innate immune response for protection against intracellular pathogens (86). Consistent with this notion, results here show that there is a significant positive association between plasma Gln concentrations and HSp70 transcript levels measured in circulating white blood cells from children with malaria. Although cellular and molecular mechanisms involved in Gln-induced HSP70 upregulation remain largely unknown, previous studies have shown that Gln increases the amount of unphosphorylated HSF-1 in the nucleus, the main regulator of the heat-stress response (23,24). Recent studies also suggest that activation of HSP70 may be mediated via O-glycosylation, nuclear translocation and transcriptional activation of Sp1 and HSF-1, as well as activation of the PI3-K/Akt pathway (87,88).

In a series of in vitro experiments presented here, we demonstrate that addition of Gln can overcome suppression of HSP70 transcripts and protein induced by PHz in a dose- and time-dependent manner. We further show that the effect of Gln appears to be mediated through a dose- and time-dependent prevention of NF-κB translocation into the nucleus, a process that we demonstrate downregulates HSP70. Previous studies have shown that Hsp70 is an important protein for regulating inflammatory mediator production of disease-promoting cytokines, such as IL-1β, IL-6 and TNF-α (42). Results presented here extend these previous findings by showing that Gln can prevent overproduction of these same cytokines in PHz-treated cells. This is extremely encouraging, since we and others have shown that elevated levels of these proinflammatory mediators are associated with enhanced disease severity in children with malaria (6,7,44).

CONCLUSION

The current study demonstrates that children with SMA have significantly reduced intracellular Hsp70 levels that appear to result from phagocytosis of PHz, a process that we show enhances translocation of NF-κB to the nucleus. Moreover, children with SMA have significantly reduced circulating Gln levels that are associated with increased susceptibility to SMA. Importantly, we show that treatment of PBMCs with Gln attenuates the inhibitory effect of PHz-induced suppression of Hsp70, nuclear translocation of NF-κB and overexpression of proinflammatory cytokines that are associated with adverse clinical outcomes in children with malarial anemia. Taken together, the results presented here describe the molecular mechanisms responsible for decreased Hsp70 in children with SMA, and support the feasibility of future studies using Gln supplementation as a therapeutic option for the treatment of SMA.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the assistance of the University of New Mexico/ Kenya Medical Research Institute (KEMRI) team (Nicholas Otieno Ondiek, Elly Ochieng Munde, Vincent Odhiambo Otieno, Angela Achieng Omondi, Lily Kisia, Anne A Ong’ondo, Christine Wasonga Ochieng, Everlyne A Modi, Joan L A Ochieng, Jacob Oyoko Odeny, Joseph Oduor, Martin Ogalo, Moses Ebugure, Moses Lokorkeju, Rodney B Mongare, Stella Mariz Akinyi Oloo and Vincent Omanje). We are also grateful to all of the parents, guardians and children who participated in the study. The authors also thank the director of KEMRI for approving publication of the manuscript.

This work was supported by National Institutes of Health Research Grants R01AI51305 and D43TW05884 (DJP). This project was also supported (in part) by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through grant no. UL1TR001449 (PK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

DISCLOSURE

The study was approved by the ethical and scientific review committees at the University of Pittsburgh, the University of New Mexico and the Kenya Medical Research Institute. A portion of this work was presented at the sixth Multilateral Initiative on Malaria Pan-African Malaria Conference, held at the International Convention Centre, Durban, South Africa, October 6-11, 2013, titled “Glutamine ameliorates hemozoin-mediated suppression of heat shock protein 70 and over-expression of proinflammatory cytokines in peripheral blood.”

REFERENCES


